Institute of Experimental Medicine CAS

Targeted and Improved Alzheimer's Disease Drug Development

norway-grants-4x tacr-en-red

Support provider:	Technology Agency of the Czech Republic KAPPA Programme
Funded:	EEA grants Norway grants
Main investigator:	University hospital Hradec Kralove, Czech Republic – assoc. prof. Ondrej Soukup, Ph.D.
Other investigators:	University of Oslo – Prof. Dr. med. Dr. rer. nat. Jens Pahnke E.F.N. Institute of Experimental Medicine CAS – Mgr. Martin Horak Ph.D. Bioinova, s.r.o. – MUDr. Peter Bauer Ph.D.
Project duration:	January 2021 – April 2024
Doba realizace:	1. 1. 2021 – 30. 4. 2024
Contact persons:	Ing. Zuzana Kodymova, Ing. Leona Markova

The aim of the project is the development of compounds for the treatment of Alzheimer´s disease (AD). The project will include an approaches of personalized medicine during the development process in the way that novel compounds will be tested in a disease in a dish (DiD) model derived from AD patients.